Teva announced the FDA approval of Copaxone (glatiramer acetate injection) 40mg/mL, a new strength of Copaxone injection. This new formulation will allow for a reduced number of injections given in a patient’s regimen.

Copaxone is indicated to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis, including those who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

RELATED: Neurologic Disorders Resource Center

The new approval is based on a Phase 3 Glatiramer Acetate Low-Frequency Administration (GALA) study of over 1,400 patients. Results showed that a subcutaneously administered dose of Copaxone 40mg/mL delivered three times weekly significantly reduced relapse rates at 12 months.

Copaxone 40mg/mL is available as single-dose prefilled syringes in 12-count cartons. The existing Copaxone 20mg/mL will continue to be available as single-dose prefilled syringes in 30-count cartons.

For more information call (800) 221-4026 or visit